Mariam Abdulaziz Alkhateeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariam Abdulaziz Alkhateeb has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Haifa Essa Alfassam
Department of Biology, College of Science, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
2 shared publications - Hany Mohamed Yehia
Department of Food Science and Nutrition, King Saud University, Riyadh 11451, Saudi Arabia
2 shared publications - Maha Abdullah Momenah
Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
2 shared publications - Manal Fawzy Elkhadragy
Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
2 shared publications - Mashael Mohammed Bin-Meferij
Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
2 shared publications - Mohamed Abdelaal Ali
Plant Production Department, Arid Lands Cultivation Research Institute, City of Scientific Research and Technological Applications (SRTA-CITY) New Borg El-Arab, Alexandria 21934, Egypt
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 126
In-silico transcriptomic characterization analysis identifies SMAD5, USP2, and CUL4A as key biomarkers and therapeutic targets in colorectal cancer
- 24 October 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 126
Open AccessIn-silico transcriptomic characterization analysis identifies SMAD5, USP2, and CUL4A as key biomarkers and therapeutic targets in colorectal cancer
- Open Access
Multi-Omics Analysis of CDKN2A (p16INK4a) in Cervical Carcinoma in the Context of Human Papillomavirus and in Endometrial Carcinoma
Background: CDKN2A (p16^INK4a^) is integral to the regulation of the RB–E2F cell-cycle checkpoint and is widely acknowledged as a surrogate marker for high-risk human papillomavirus (HPV)-related cervical neoplasia. Nevertheless, its diagnostic and prognostic significance in uterine corpus endometrial carcinoma (UCEC), a predominantly HPV-independent malignancy, remains inadequately characterized. This study utilized an integrated multi-omics approach to examine CDKN2A dysregulation in cervical squamous cell carcinoma (CESC) and UCEC. Methods: Pan-cancer and tumor–normal differential expression analyses were performed using TIMER2.0 and GEPIA2 (TCGA/GTEx). Clinicopathological correlations were assessed with UALCAN. Protein expression patterns were analyzed using immunohistochemistry data from the Human Protein Atlas (HPA). Prognostic significance and immune-infiltration associations were evaluated using TCGA survival data and TIMER modules. Independent transcriptomic validation and diagnostic classification performance were assessed using GEO datasets GSE9750 (CESC) and GSE63678 (UCEC), including ROC-AUC analysis with cross-validation. Results: Integrated analyses revealed elevated CDKN2A expression in both CESC and UCEC across multiple transcriptomic cohorts, with pronounced tumor-specific protein expression on immunohistochemistry. TCGA-only tumor–normal RNA comparisons were non-significant, likely due to limited normal sample representation. In independent GEO cohorts, CDKN2A exhibited excellent tumor–normal discrimination in CESC (AUC = 0.982) and moderate discrimination in UCEC (AUC = 0.761). Survival analysis indicated tumor-specific patterns, with limited prognostic stratification in CESC and context-dependent associations in UCEC. Immune-infiltration analysis suggested tumor-type-specific interactions between CDKN2A expression and immune cell subsets. Conclusions: CDKN2A exhibits strong diagnostic performance in HPV-associated cervical cancer and moderate, cohort-dependent discriminatory ability in endometrial carcinoma. These findings reinforce its established diagnostic role in CESC and propose adjunctive utility in UCEC, underscoring the importance of tumor-contextual interpretation of CDKN2A expression in gynecologic malignancies.
Open AccessMulti-Omics Analysis of CDKN2A (p16INK4a) in Cervical Carcinoma in the Context of Human Papillomavirus and in Endometrial Carcinoma
Background: CDKN2A (p16^INK4a^) is integral to the regulation of the RB–E2F cell-cycle checkpoint and is widely acknowledged as a surrogate marker for high-risk human papillomavirus (HPV)-related cervical neoplasia. Nevertheless, its diagnostic and prognostic significance in uterine corpus endometrial carcinoma (UCEC), a predominantly HPV-independent malignancy, remains inadequately characterized. This study utilized an integrated multi-omics approach to examine CDKN2A dysregulation in cervical squamous cell carcinoma (CESC) and UCEC. Methods: Pan-cancer and tumor–normal differential expression analyses were performed using TIMER2.0 and GEPIA2 (TCGA/GTEx). Clinicopathological correlations were assessed with UALCAN. Protein expression patterns were analyzed using immunohistochemistry data from the Human Protein Atlas (HPA). Prognostic significance and immune-infiltration associations were evaluated using TCGA survival data and TIMER modules. Independent transcriptomic validation and diagnostic classification performance were assessed using GEO datasets GSE9750 (CESC) and GSE63678 (UCEC), including ROC-AUC analysis with cross-validation. Results: Integrated analyses revealed elevated CDKN2A expression in both CESC and UCEC across multiple transcriptomic cohorts, with pronounced tumor-specific protein expression on immunohistochemistry. TCGA-only tumor–normal RNA comparisons were non-significant, likely due to limited normal sample representation. In independent GEO cohorts, CDKN2A exhibited excellent tumor–normal discrimination in CESC (AUC = 0.982) and moderate discrimination in UCEC (AUC = 0.761). Survival analysis indicated tumor-specific patterns, with limited prognostic stratification in CESC and context-dependent associations in UCEC. Immune-infiltration analysis suggested tumor-type-specific interactions between CDKN2A expression and immune cell subsets. Conclusions: CDKN2A exhibits strong diagnostic performance in HPV-associated cervical cancer and moderate, cohort-dependent discriminatory ability in endometrial carcinoma. These findings reinforce its established diagnostic role in CESC and propose adjunctive utility in UCEC, underscoring the importance of tumor-contextual interpretation of CDKN2A expression in gynecologic malignancies.
- 13 February 2026
- Published by Springer Nature in Biological Trace Element Research
- Vol. 204 (6) , 4214-4239
Omega 3 Fatty Acids Mitigate Monosodium Glutamate (MSG)-Induced Developmental Toxicity via Hepcidin/NF-κB Pathway Modulation and Iron Homeostasis Restoration in Male Rats
- 13 February 2026
- Published by Springer Nature in Biological Trace Element Research
- Vol. 204 (6) , 4214-4239
Omega 3 Fatty Acids Mitigate Monosodium Glutamate (MSG)-Induced Developmental Toxicity via Hepcidin/NF-κB Pathway Modulation and Iron Homeostasis Restoration in Male Rats
- 7 January 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 2897-2910
In Silico Pharmacological Evaluation of Azadirachta indica Phytochemicals Targeting Thalassemia-Associated Genes and Proteins
Thalassemia is an inherited hemoglobin disease characterized by persistent anemia, oxidative and iron overload due to transfusion, creating severe clinical and economic issues in South Asia. The adverse effects and adverse effects of current treatment options highlight the need to have safer and multi-target options. In this study, a comprehensive in silico pharmacoinformatic methodology was applied to determine the therapeutic value of Azadirachta indica (Neem) phytochemicals on thalassemia-related targets. One hundred and five phytocompounds were shortlisted, and the number of those passing drug-likeness and ADMET filters evaluated at SwissADME, MolSoft (v6.8) and ADMETlab 3.0 was 350. The intersecting genes were predicted by target prediction with SwissTargetPrediction and functionally enriched with the help of DAVID (v6.8) and KEGG (v113.0). Significantly enriched pathways were Lipid and Atherosclerosis (Benjamini [ ] 0.0236), Apoptosis ([ ] 0.043) and Chemical Carcinogenesis ([ ] 0.00167). The central hub genes were TNF, TP53, PPARG, CYP3A44 and found by the network analysis with the help of STRING (v11.5) and Cytoscape (v3.10.0). Molecular docking was done using PyRx (v0.9.8) with AutoDock Vina (v1.2.3) being implemented. The highest affinity of the screened compounds was found to be Naringenin, with a binding energy of −9.8 kcal/mol (PDB ID: 1v04), and it was greater than that of Hydroxyurea (−8.9 kcal/mol), Deferiprone (−5.3 kcal/mol) and Deferasirox (−5.3 kcal/mol). Quercetin, Luteolin and Genistein had a good binding profile with the presence of stable hydrogen bonding and [ ]–[ ] interactions as illustrated in PyMOL (v2.5). This cumulative computational pipeline lays significant evidence that phytochemicals derived from Neem are prime multi-target lead compounds to use as adjuncts in the treatment of thalassemia. These findings require further confirmation through molecular dynamics simulations and experimental confirmation.
- 7 January 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 2897-2910
In Silico Pharmacological Evaluation of Azadirachta indica Phytochemicals Targeting Thalassemia-Associated Genes and Proteins
Thalassemia is an inherited hemoglobin disease characterized by persistent anemia, oxidative and iron overload due to transfusion, creating severe clinical and economic issues in South Asia. The adverse effects and adverse effects of current treatment options highlight the need to have safer and multi-target options. In this study, a comprehensive in silico pharmacoinformatic methodology was applied to determine the therapeutic value of Azadirachta indica (Neem) phytochemicals on thalassemia-related targets. One hundred and five phytocompounds were shortlisted, and the number of those passing drug-likeness and ADMET filters evaluated at SwissADME, MolSoft (v6.8) and ADMETlab 3.0 was 350. The intersecting genes were predicted by target prediction with SwissTargetPrediction and functionally enriched with the help of DAVID (v6.8) and KEGG (v113.0). Significantly enriched pathways were Lipid and Atherosclerosis (Benjamini [ ] 0.0236), Apoptosis ([ ] 0.043) and Chemical Carcinogenesis ([ ] 0.00167). The central hub genes were TNF, TP53, PPARG, CYP3A44 and found by the network analysis with the help of STRING (v11.5) and Cytoscape (v3.10.0). Molecular docking was done using PyRx (v0.9.8) with AutoDock Vina (v1.2.3) being implemented. The highest affinity of the screened compounds was found to be Naringenin, with a binding energy of −9.8 kcal/mol (PDB ID: 1v04), and it was greater than that of Hydroxyurea (−8.9 kcal/mol), Deferiprone (−5.3 kcal/mol) and Deferasirox (−5.3 kcal/mol). Quercetin, Luteolin and Genistein had a good binding profile with the presence of stable hydrogen bonding and [ ]–[ ] interactions as illustrated in PyMOL (v2.5). This cumulative computational pipeline lays significant evidence that phytochemicals derived from Neem are prime multi-target lead compounds to use as adjuncts in the treatment of thalassemia. These findings require further confirmation through molecular dynamics simulations and experimental confirmation.
- 6 January 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 2447-2467
Elucidating DENND5A as a Therapeutic Target for Hepatocellular Carcinoma with Integrative Insights from Spatial Transcriptomics and Molecular Docking Approaches
Hepatocellular Carcinoma (LIHC) represents the most prevalent variant of liver malignancy and constitutes a primary contributor to cancer-associated mortality, frequently identified at advanced stages of the disease. This investigation examines the significance of the DENND5A oncogene in LIHC through a thorough examination of its expression levels, methylation status, somatic mutations and interactions with the immune microenvironment. By employing diverse bioinformatics platforms — including GEPIA2, OncoDB, cBioPortal, PreCog and TIMER 2.0 — we discerned a pronounced overexpression of DENND5A, thereby establishing it as a salient biomarker for LIHC. Methylation assessments revealed hypomethylation in LIHC specimens, whereas somatic mutations were found to correlate with elevated mRNA levels, underscoring DENND5A as a promising therapeutic candidate. Moreover, this research investigates the therapeutic ability of a bioactive–antibiotic conjugate comprising Eridictyol and carbapenem via molecular docking by using PyRx. The molecular docking results show that Eriodictyol has a binding energy of −7.4 kcal/mol, while carbapenem has a binding affinity of −4.1 kcal/mol. The E-C conjugate was determined to have a binding affinity of −9.5 kcal/mol. The Swiss ADMET evaluation revealed advantageous pharmacokinetic characteristics, including commendable human intestinal absorption, albeit with restricted permeability across the blood–brain barrier. Molecular dynamics simulations validated the structural integrity and dynamic behavior of the Eriodictyol–Carbapenem conjugate in conjunction with DENND5A, thereby indicating its promise as an innovative therapeutic approach for hepatocellular carcinoma. Our results position DENND5A as a noteworthy biomarker and therapeutic target for LIHC, with the Eriodictyol–Carbapenem conjugate presenting a novel pathway for treatment.
- 6 January 2026
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 2447-2467
Elucidating DENND5A as a Therapeutic Target for Hepatocellular Carcinoma with Integrative Insights from Spatial Transcriptomics and Molecular Docking Approaches
Hepatocellular Carcinoma (LIHC) represents the most prevalent variant of liver malignancy and constitutes a primary contributor to cancer-associated mortality, frequently identified at advanced stages of the disease. This investigation examines the significance of the DENND5A oncogene in LIHC through a thorough examination of its expression levels, methylation status, somatic mutations and interactions with the immune microenvironment. By employing diverse bioinformatics platforms — including GEPIA2, OncoDB, cBioPortal, PreCog and TIMER 2.0 — we discerned a pronounced overexpression of DENND5A, thereby establishing it as a salient biomarker for LIHC. Methylation assessments revealed hypomethylation in LIHC specimens, whereas somatic mutations were found to correlate with elevated mRNA levels, underscoring DENND5A as a promising therapeutic candidate. Moreover, this research investigates the therapeutic ability of a bioactive–antibiotic conjugate comprising Eridictyol and carbapenem via molecular docking by using PyRx. The molecular docking results show that Eriodictyol has a binding energy of −7.4 kcal/mol, while carbapenem has a binding affinity of −4.1 kcal/mol. The E-C conjugate was determined to have a binding affinity of −9.5 kcal/mol. The Swiss ADMET evaluation revealed advantageous pharmacokinetic characteristics, including commendable human intestinal absorption, albeit with restricted permeability across the blood–brain barrier. Molecular dynamics simulations validated the structural integrity and dynamic behavior of the Eriodictyol–Carbapenem conjugate in conjunction with DENND5A, thereby indicating its promise as an innovative therapeutic approach for hepatocellular carcinoma. Our results position DENND5A as a noteworthy biomarker and therapeutic target for LIHC, with the Eriodictyol–Carbapenem conjugate presenting a novel pathway for treatment.
- 19 June 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- p. 1-18
Investigation of Parkinson’s Disease: Synthesis, In Vitro and In Silico Screening of Imidazopyridine-Derived Thiadiazole-Bearing Benzimidazole Scaffolds as Effective MAO-A and MAO-B Inhibitors
With the increasing prevalence of neurodegenerative diseases (NDs), novel classes of compounds targeting monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B) are rapidly emerging as promising candidates for their treatment. In this context, we have synthesized a series of novel imidazopyridine-derived thiadiazole-bearing benzimidazole compounds as potential MAO-A and MAO-B inhibitors. These compounds were structurally elucidated by 1H NMR, [ ]C NMR and Mass analysis. Most of the compounds displayed good inhibition in the range of (IC[ ]value 23.30 ± 2.70 − 57.80 ± 6.60 [ ]M for hMAO-A and 23.60 ± 1.90 − 59.70 ± 6.80 [ ]M) in comparison of reference drugs toloxatone (IC[ ]34.50 ± 3.20 [ ]M) and Lazabemide (IC[ ]39.90 ± 4.40 [ ]M), respectively. Compounds 11, 8, 2, 10 and 7 demonstrated IC[ ] 23.30 ± 2.70 − 29.40 ± 3.70 [ ]M against MAO-A and IC[ ] 23.60 ± 1.90 − 30.30 ± 3.30 against MAO-B, indicating significant activity compared to the standard inhibitors. Additionally, molecular docking analysis was performed to predict the binding modes of the newly synthesized derivatives with the MAO-A and MAO-B enzymes. The docking results were aligned well with the findings from the in vitro studies, exhibiting hydrogen bonding, [ ]-donor hydrogen bond, [ ]–[ ]-T-shaped, [ ]–[ ]-stacking, [ ]-alkyl, [ ]-anion, [ ]-sigma, [ ]-sulfur and halogen (fluorine) interactions, further supporting their potential as effective enzyme inhibitors.
- 19 June 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- p. 1-18
Investigation of Parkinson’s Disease: Synthesis, In Vitro and In Silico Screening of Imidazopyridine-Derived Thiadiazole-Bearing Benzimidazole Scaffolds as Effective MAO-A and MAO-B Inhibitors
With the increasing prevalence of neurodegenerative diseases (NDs), novel classes of compounds targeting monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B) are rapidly emerging as promising candidates for their treatment. In this context, we have synthesized a series of novel imidazopyridine-derived thiadiazole-bearing benzimidazole compounds as potential MAO-A and MAO-B inhibitors. These compounds were structurally elucidated by 1H NMR, [ ]C NMR and Mass analysis. Most of the compounds displayed good inhibition in the range of (IC[ ]value 23.30 ± 2.70 − 57.80 ± 6.60 [ ]M for hMAO-A and 23.60 ± 1.90 − 59.70 ± 6.80 [ ]M) in comparison of reference drugs toloxatone (IC[ ]34.50 ± 3.20 [ ]M) and Lazabemide (IC[ ]39.90 ± 4.40 [ ]M), respectively. Compounds 11, 8, 2, 10 and 7 demonstrated IC[ ] 23.30 ± 2.70 − 29.40 ± 3.70 [ ]M against MAO-A and IC[ ] 23.60 ± 1.90 − 30.30 ± 3.30 against MAO-B, indicating significant activity compared to the standard inhibitors. Additionally, molecular docking analysis was performed to predict the binding modes of the newly synthesized derivatives with the MAO-A and MAO-B enzymes. The docking results were aligned well with the findings from the in vitro studies, exhibiting hydrogen bonding, [ ]-donor hydrogen bond, [ ]–[ ]-T-shaped, [ ]–[ ]-stacking, [ ]-alkyl, [ ]-anion, [ ]-sigma, [ ]-sulfur and halogen (fluorine) interactions, further supporting their potential as effective enzyme inhibitors.
- 5 March 2025
- Published by Springer Nature in Journal of Materials Research
- Vol. 40 (7) , 1009-1024
Novel synthesis of CNTs/Cu nanodots-arabic gum nano-hybrid composites induce cytotoxicity and apoptosis in human breast and lung cancer cell lines
- 5 March 2025
- Published by Springer Nature in Journal of Materials Research
- Vol. 40 (7) , 1009-1024
Novel synthesis of CNTs/Cu nanodots-arabic gum nano-hybrid composites induce cytotoxicity and apoptosis in human breast and lung cancer cell lines
- Open Access
- 8 October 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (9) , 74-80
CRISPR-Cas9 guided RNA-based model for the silencing of spinal bulbar muscular atrophy: A functional genetic disorder
This study explores a novel therapeutic approach for spinal bulbar muscular atrophy (SBMA), a neurodegenerative disorder caused by a mutation in the Androgen Receptor (AR) gene. The aim is to investigate the potential of CRISPR-Cas9 technology in targeting the mutant AR gene to inhibit its production. The objectives include assessing the accuracy and efficacy of CRISPR-Cas9 guided RNAs in silencing the mutant gene and evaluating the feasibility of this approach as a treatment for SBMA. Computational and in-silico approaches are used to evaluate the feasibility of using CRISPR-Cas9 technology for treating SBMA. Computational analysis is used to design CRISPR-Cas9 guided RNAs targeting the mutant AR gene, assessing their on-target and off-target scores, GC content, and structural accuracy. In-silico simulations predict the potential therapeutic outcomes of the CRISPR-Cas9 approach in an artificial environment. Three guided RNA (gRNA) sequences were designed using the CHOPCHOP tool, targeting specific regions of the AR gene with high efficiency and 100% match. These gRNAs demonstrated effective targeting with minimal off-target scores and optimal GC content. Additionally, lentiCRISPR v2 plasmids were designed for the delivery of CRISPR materials, enabling high-efficiency multiplex genome editing of the AR gene. Thermodynamic ensemble predictions indicated favorable secondary structure stability of the designed gRNAs, further supporting their suitability for gene editing. The evaluation of designed gRNAs confirmed their strong binding ability to the target sequences, validating their potential as effective tools for genome editing. The study highlights the potential of CRISPR-Cas9 technology for targeting the Androgen Receptor gene associated with spinal bulbar muscular atrophy (SBMA). The findings support the feasibility of this approach for gene editing and suggest further exploration in preclinical and clinical settings. Recommendations include continued research to optimize CRISPR-Cas9 delivery methods and enhance specificity for therapeutic applications in SBMA.
- 8 October 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (9) , 74-80
Open AccessCRISPR-Cas9 guided RNA-based model for the silencing of spinal bulbar muscular atrophy: A functional genetic disorder
This study explores a novel therapeutic approach for spinal bulbar muscular atrophy (SBMA), a neurodegenerative disorder caused by a mutation in the Androgen Receptor (AR) gene. The aim is to investigate the potential of CRISPR-Cas9 technology in targeting the mutant AR gene to inhibit its production. The objectives include assessing the accuracy and efficacy of CRISPR-Cas9 guided RNAs in silencing the mutant gene and evaluating the feasibility of this approach as a treatment for SBMA. Computational and in-silico approaches are used to evaluate the feasibility of using CRISPR-Cas9 technology for treating SBMA. Computational analysis is used to design CRISPR-Cas9 guided RNAs targeting the mutant AR gene, assessing their on-target and off-target scores, GC content, and structural accuracy. In-silico simulations predict the potential therapeutic outcomes of the CRISPR-Cas9 approach in an artificial environment. Three guided RNA (gRNA) sequences were designed using the CHOPCHOP tool, targeting specific regions of the AR gene with high efficiency and 100% match. These gRNAs demonstrated effective targeting with minimal off-target scores and optimal GC content. Additionally, lentiCRISPR v2 plasmids were designed for the delivery of CRISPR materials, enabling high-efficiency multiplex genome editing of the AR gene. Thermodynamic ensemble predictions indicated favorable secondary structure stability of the designed gRNAs, further supporting their suitability for gene editing. The evaluation of designed gRNAs confirmed their strong binding ability to the target sequences, validating their potential as effective tools for genome editing. The study highlights the potential of CRISPR-Cas9 technology for targeting the Androgen Receptor gene associated with spinal bulbar muscular atrophy (SBMA). The findings support the feasibility of this approach for gene editing and suggest further exploration in preclinical and clinical settings. Recommendations include continued research to optimize CRISPR-Cas9 delivery methods and enhance specificity for therapeutic applications in SBMA.
- Open Access
Harnessing Desmochloris edaphica Strain CCAP 6006/5 for the Eco-Friendly Synthesis of Silver Nanoparticles: Insights into the Anticancer and Antibacterial Efficacy
Microalgae-mediated nanoparticle (NP) biosynthesis is a promising green synthesis method that overcomes the challenges of conventional synthesis methods. The novel Desmochloris edaphica strain CCAP 6006/5 was isolated, purified, and characterized morphologically and genetically. GC-MS analysis of the algal biomass (DBio) phytochemicals showed the abundance for elaidic acid (18.36%) and monoolein (17.37%). UV-VIS spectroscopy helped analyze the effects of the AgNO3 concentration, algal/silver nitrate ratio, temperature, reaction time, illumination, and pH on AgNP synthesis. DBio extract or cell-free medium (DSup) of D. edaphica successfully biosynthesized small silver NPs (AgNPs), namely, DBio@AgNPs and DSup@AgNPs, under optimum reaction conditions. TEM and SEM showed a quasi-spherical shape, with average diameters of 15.0 ± 1.0 nm and 12.0 ± 0.8 nm, respectively. EDx and mapping analyses revealed that silver was the main element, the NP hydrodynamic diameters were 77.9 and 62.7 nm, and the potential charges were −24.4 and −25.8 mV, respectively. FTIR spectroscopy revealed that the DBio@AgNPs, and DSup@AgNPs were coated with algal functional groups, probably derived from algal proteins, fatty acids, or polysaccharides, representing reductant and stabilizer molecules from the synthesis process. They showed significant anticancer activity against breast cancer cells (MCF-7), low toxicity against normal kidney cells (Vero), and potent inhibitory activity against Staphylococcus aureus, Bacillus subtilis, and Shigella flexneri. D. edaphica is a novel biomachine for synthesizing small, stable and potent therapeutic AgNPs.
Open AccessHarnessing Desmochloris edaphica Strain CCAP 6006/5 for the Eco-Friendly Synthesis of Silver Nanoparticles: Insights into the Anticancer and Antibacterial Efficacy
Microalgae-mediated nanoparticle (NP) biosynthesis is a promising green synthesis method that overcomes the challenges of conventional synthesis methods. The novel Desmochloris edaphica strain CCAP 6006/5 was isolated, purified, and characterized morphologically and genetically. GC-MS analysis of the algal biomass (DBio) phytochemicals showed the abundance for elaidic acid (18.36%) and monoolein (17.37%). UV-VIS spectroscopy helped analyze the effects of the AgNO3 concentration, algal/silver nitrate ratio, temperature, reaction time, illumination, and pH on AgNP synthesis. DBio extract or cell-free medium (DSup) of D. edaphica successfully biosynthesized small silver NPs (AgNPs), namely, DBio@AgNPs and DSup@AgNPs, under optimum reaction conditions. TEM and SEM showed a quasi-spherical shape, with average diameters of 15.0 ± 1.0 nm and 12.0 ± 0.8 nm, respectively. EDx and mapping analyses revealed that silver was the main element, the NP hydrodynamic diameters were 77.9 and 62.7 nm, and the potential charges were −24.4 and −25.8 mV, respectively. FTIR spectroscopy revealed that the DBio@AgNPs, and DSup@AgNPs were coated with algal functional groups, probably derived from algal proteins, fatty acids, or polysaccharides, representing reductant and stabilizer molecules from the synthesis process. They showed significant anticancer activity against breast cancer cells (MCF-7), low toxicity against normal kidney cells (Vero), and potent inhibitory activity against Staphylococcus aureus, Bacillus subtilis, and Shigella flexneri. D. edaphica is a novel biomachine for synthesizing small, stable and potent therapeutic AgNPs.